A pivotal Phase 2 clinical trial of BI 860585 with a standard-of-care treatment for breast cancer
Latest Information Update: 05 Jan 2019
At a glance
- Drugs XP 105 (Primary)
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Xynomic Pharmaceuticals
Most Recent Events
- 05 Jan 2019 New trial record
- 20 Dec 2018 According to a Xynomic Pharma media release, plans to initiate the trial in the next 6-9 months.